Original Article: Streptokinase Modifies in Vitro Platelet Aggregation by Two Mechanisms: Reduced Aggregation due to Fibrinogenolysis and Enhanced Aggregation via an Immunological Reaction.

Both inhibition and enhancement of platelet aggregation have been observed after exposure to streptokinase (SK) in vitro. Recently we have shown that inhibition of aggregation appears to be related to the fraction containing the fibrinogen degradation product, fragment E. In addition, SK may initiate platelet aggregation by a mechanism involving specific anti-SK antibodies and plasminogen. Two monoclonal antibodies (MoAbs) (PL2-49 and LeoA1) were used to assess the immunological activation of platelets in SK-induced platelet aggregation and in SK-enhanced ADP-induced platelet aggregation. The anti-SK titers in healthy volunteers' and patients' (previously treated with SK for acute myocardial infarction) plasma, were measured using a one-site non-competitive ELISA. Serum from patients was used for the purification of IgG anti-SK by affinity chromatography. We confirmed that the degree of fibrinogen degradation is a major determinant of the aggregation inhibition induced by SK. SK-induced platelet aggregation and SK-enhanced ADP-induced platelet aggregation require the interaction of the Fc domain of the anti-SK antibodies with the FcyRII located on the platelet membrane, since they are blocked by the MoAb IV-3 directed against FcyRII. Classification of the subjects according to their responses to specific MoAbs (PL2-49 and LeoA1) supports the essential role played by immunological activation of platelets in SK-induced platelet aggregation and in SK-enhanced ADP-induced platelet aggregation. The ability of anti-SK antibodies to promote SK-induced platelet aggregation and SK-enhanced ADP-induced platelet aggregation, seems to result from the interaction between two separate mechanisms: the fist mechanism is based on immunological activation of platelets and the second is related to the intervention of a defined subset of anti-SK antibodies.

[1]  F. Bachmann.  Development of antibodies against perorally and rectally administered streptokinase in man. , 1968, The Journal of laboratory and clinical medicine.

[2]  R. Carroll,et al.  Platelet activation by CD9 monoclonal antibodies is mediated by the FCγII receptor , 1990 .

[3]  V. Marder,et al.  Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction. , 1992, American heart journal.

[4]  J. Tcheng,et al.  Platelet and Thrombin Inhibitors as Adjuncts to Thrombolytic Therapy and Percutaneous Coronary Interventions: A Review , 1997 .

[5]  S. Heptinstall,et al.  Effects of streptokinase and recombinant tissue plasminogen activator on platelet aggregation in whole blood. , 1990, Platelets.

[6]  D. M. Weir,et al.  Handbook of experimental immunology , 1967 .

[7]  J. Loscalzo,et al.  Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins. , 1990, Circulation research.

[8]  J. Hoffmann,et al.  Platelet function during thrombolytic therapy with anistreplase , 1993 .

[9]  J. Kelton,et al.  Platelet IgG Fc receptor , 1987, American journal of hematology.

[10]  C. Anderson,et al.  Human platelet Fc receptor for immunoglobulin G. Identification as a 40,000-molecular-weight membrane protein shared by monocytes. , 1985, The Journal of clinical investigation.

[11]  B. Sobel,et al.  The nature of interactions between tissue-type plasminogen activator and platelets. , 1990, Thrombosis research.

[12]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[13]  G. Born,et al.  The aggregation of blood platelets , 1963, The Journal of physiology.

[14]  D. Mathey,et al.  Effects of streptokinase, urokinase, and recombinant tissue plasminogen activator on platelet aggregability and stability of platelet aggregates. , 1990, Cardiovascular research.

[15]  H. Gralnick,et al.  Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods. , 1975 .

[16]  G. Burns,et al.  Heterogeneity of Platelet Fc-receptor-dependent Response to Activating Monoclonal Antibodies. , 1992, Platelets.

[17]  M. Samama,et al.  PL2‐49, a monoclonal antibody against glycoprotein IIb which is a platelet activator , 1989, British journal of haematology.

[18]  A. Schafer,et al.  Plasmin inhibition of platelet function and of arachidonic acid metabolism. , 1985, The Journal of clinical investigation.

[19]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[20]  S. Niewiarowski,et al.  Plasmin-induced platelet aggregation and platelet release reaction. Effects on hemostasis. , 1973, The Journal of clinical investigation.

[21]  G. Burns,et al.  Characterization of a novel membrane glycoprotein involved in platelet activation. , 1989, The Journal of biological chemistry.

[22]  J. Conard,et al.  Tests d'agrégation plaquettaire dans 26 cas de thrombopénies induites par l'héparine (TIH). Problèmes méthodologiques, diagnostiques et aspects thérapeutiques. , 1987 .

[23]  G. FitzGerald,et al.  Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. , 1988, Circulation.

[24]  G. FitzGerald,et al.  Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. , 1989, Circulation.

[25]  G. Helft,et al.  Human Anti-Streptokinase Antibodies Induce Platelet Aggregation in an Fc Receptor (CD32) Dependent Manner , 1995, Thrombosis and Haemostasis.

[26]  J. Cawley,et al.  A monoclonal antibody to a 67 kD cell membrane glycoprotein directly induces persistent platelet aggregation independently of granule secretion , 1991, British journal of haematology.

[27]  D. Vaughan,et al.  Streptokinase‐Induced Platelet Aggregation: Prevalence and Mechanism , 1991, Circulation.

[28]  J. Loscalzo,et al.  STREPTOKINASE-INDUCED, ANTIBODY-MEDIATED PLATELET AGGREGATION: A POTENTIAL CAUSE OF CLOT PROPAGATION IN VIVO , 1988, Thrombosis and Haemostasis.

[29]  A. Fletcher,et al.  The clearance of heterologous protein from the circulation of normal and immunized man. , 1958, The Journal of clinical investigation.

[30]  H. Ferres,et al.  Comparison of the effects of streptokinase, t-PA and APSAC on human platelet aggregation in vitro in the absence and presence of aspirin. , 1990, Thrombosis research.

[31]  M. Samama,et al.  Streptokinase and APSAC Inhibit Platelet Aggregation In Vitro by Fibrinogenolysis: Effect of Plasma Fibrinogen Degradation Products X and E , 1995 .

[32]  C McRae,et al.  Myocardial infarction. , 2019, Australian family physician.

[33]  L. Sauvage,et al.  Platelet Consumption by Arterial Prostheses: The Effects of Endothelialization and Pharmacologic Inhibition of Platelet Function , 1977, Annals of surgery.

[34]  T. Lecompte,et al.  In Vitro Effect of Plasmin on Human Platelet Function in Plasma: Inhibition of Aggregation Caused by Fibrinogenolysis , 1992, Circulation.

[35]  R. Stockley,et al.  Immunoglobulin response to intravenous streptokinase in acute myocardial infarction. , 1991, British heart journal.

[36]  C. Anderson,et al.  Human Fc gamma receptors: stable inter-donor variation in quantitative expression on platelets correlates with functional responses. , 1987, Journal of immunology.

[37]  C. Anderson,et al.  Structural polymorphism of the human platelet Fc gamma receptor. , 1988, Journal of immunology.